Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its competitors? We will compare Black Titan to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk.
Insider and Institutional Ownership
57.9% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 53.7% of Black Titan shares are owned by insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Black Titan and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | -$4.71 million | -0.58 |
| Black Titan Competitors | $233.35 million | -$56.06 million | -11.25 |
Risk and Volatility
Black Titan has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.54, suggesting that their average share price is 46% less volatile than the S&P 500.
Profitability
This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -37.79% | -997.78% | -64.21% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Black Titan and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 96 | 199 | 216 | 12 | 2.28 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 137.60%. Given Black Titan’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its competitors.
Summary
Black Titan competitors beat Black Titan on 7 of the 12 factors compared.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
